A drug testing industry association and a pharmaceutical company are asking a federal court to block the Trump administration from moving forward with federal cannabis rescheduling while ongoing litigation challenging the reform is considered—arguing that “marijuana abuse has dangerous, lifelong consequences—especially for adolescents and pregnant women.”
The new filing claims that “by cutting taxes on cannabis companies,” federal rescheduling “will stimulate the industry and increase marijuana abuse.”
The brief, filed on Thursday, comes in response to the Department of Justice’s opposition to the drug testing group and pharma company’s motion to pause the rescheduling move.
The government, in its brief earlier this month, noted that the entities challenging cannabis rescheduling have “pocketbook interests served by keeping all marijuana in schedule I” and are not suitable challengers to the reform because they are not the “intended beneficiaries” of the Controlled Substances Act (CSA).
The filing this week from opponents, however, claims that DOJ’s arguments on standing are “meritless diversions from its indefensible position on the merits.”
“Movants need not be ‘intended beneficiaries of the CSA,’” it says. “Nor does it matter that movants have ‘pocketbook interests’ at stake while the CSA has broader objectives aimed at the general welfare. ”
The U.S.
Read full article on Marijuana Moment
